Healthcare Equipment and Supplies
Company Overview of Bayer HealthCare LLC
Bayer HealthCare LLC develops, manufactures, and markets healthcare and medical products. The company offers blood glucose monitoring systems, diabetes self-care software, and lancing devices; and YAZ, a low-dose oral contraceptive. It also provides diagnostic testing for urinalysis, DCA, immunology, blood gas, and hematology; molecular and clinical chemistry testing to assess and manage health in a myriad of disease states, including cardiovascular, kidney and infectious diseases, oncology, and virology; and Bayer Migraine Formula, an over-the-counter medication designed to relieve migraine pain and accompanying symptoms, including nausea, phonophobia, and photophobia. The company offers an...
100 Bayer Road
Pittsburgh, PA 15205
Founded in 2002
Key Executives for Bayer HealthCare LLC
President and General Manager, Animal Health Division, North America
President of Animal Health Division for North America and General Manager of Animal Health Division for North America
President of Consumer Care Division
Senior Vice President, Global Head, Product Supply -Biotech and Site Head
Bayer HealthCare Representative U.S.A.
Compensation as of Fiscal Year 2015.
Bayer HealthCare LLC Key Developments
Motley Rice Files Two Suits for California Women against Bayer Corp., Bayer Healthcare LLC, Bayer Essure, Inc., Bayer Healthcare Pharmaceuticals, Inc. and Bayer AG
Jan 14 16
Motley Rice LLC has filed two suits for California women against Bayer Corp., Bayer Healthcare LLC, Bayer Essure Inc., (formerly known as Conceptus Inc.), Bayer Healthcare Pharmaceuticals Inc., and Bayer AG for personal injuries and 10 alleged counts, including fraudulent concealment and negligent misrepresentation of the permanent birth control device Essure®. Filed in the Superior Court for the State of California County of Santa Clara for Deanna Alonzo of Fillmore, Calif. and Desirea Harvey of Orangevale, Calif., the suits allege that Essure has permanently injured and altered the quality of life of these two young mothers and has left both with no other option than to have a hysterectomy to deal with the complications related to Essure. Essure is a permanent birth control procedure that is a type of tubal sterilization that does not require an incision. During the procedure, a metal spring-like device wound with synthetic fibers is implanted in the fallopian tubes. The metal portion of the device consists of a stainless steel inner coil and an expanding nickel titanium outer coil. The fibers are designed to encourage surrounding tissue to adhere to the device, ultimately creating a barrier of tissue to block sperm from reaching the eggs. Essure was approved by the FDA in 2002, and as of May 2015, there were more than 5,000 reports from both doctors and women to the FDA claiming Essure caused serious side effects, including 11 deaths. Five of those deaths were fetal deaths that occurred in women who became pregnant despite undergoing the Essure procedure.
Bayer Receives FDA Approval for BETACONNECT - Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment
Sep 26 15
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) approved BETACONNECT, the first and only electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). BETACONNECT will be available exclusively to BETASERON (interferon beta-1b) patients beginning in early 2016. BETASERON is a prescription medicine used to reduce the number of relapses in people with relapsing forms of multiple sclerosis. This includes people who have had their first symptoms of multiple sclerosis and have an MRI consistent with multiple sclerosis. BETASERON will not cure MS but may decrease the number of flare-ups of the disease. After completing the preparation of BETASERON, patients may administer BETASERON by using the BETACONNECT, which should only be used with the syringes provided in the BETASERON packaging.
U.S. Food & Drug Administration Approves Bayer HealthCare's Finacea(R) (azelaic acid) Foam 15% for Topical Treatment of the Inflammatory Papules and Pustules of Mild to Moderate Rosacea
Jul 31 15
Bayer HealthCare announced that the U.S. Food & Drug Administration (FDA) has approved Finacea® (azelaic acid) Foam, 15% for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Papulopustular rosacea is a skin disease causing inflammatory lesions (papules and pustules) on the nose, cheeks, chin and forehead. Finacea® Foam was developed as part of a research and development collaboration between Foamix Pharmaceuticals Ltd. and Bayer HealthCare, utilizing Foamix's proprietary foam technology platform. According to a license agreement between the two companies, Foamix is entitled to royalties and certain milestone payments upon commercialization of Finacea® Foam.
Similar Private Companies By Industry
Recent Private Companies Transactions